Dutch Authorize Manufacture Of Vaccinogen’s New Anti-Colon Cancer Vaccine; License Clears Path To European Production, Final FDA Trial
May 15th 2008Drug InformationColorectal Cancer
Vaccinogen Inc. said Dutch health authorities licensed it to manufacture its break-through OncoVAX anti-colon cancer vaccine, immediately clearing the path to more than US$100 million of potential European sales.The Dutch approval of the company’s facility based in Emmen, The Netherlands also paves the way to its pivotal US FDA Phase IIIb clinical trial — the final step before the vaccine can be sold in the United States.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
